AbbVie

Voyager clears Neurocrine agreement for Parkinson's gene therapy Voyager Therapeutics is signing a collaboration agreement with Neurocrine Biosciences that will remunerate the Cambridge, Massachusetts-based biotech USD 165 million upfront. In return, Neurocrine benefits certain rights to four gene therapy progra...

Prometic bags USD 50 Million stock sale option to ease a cash crunch Prometic Life Sciences got into an agreement for selling USD 50 million in stock. This gives Prometic a way to escape its current financial pressures. Canada-based Prometic was asked by the FDA to make and validate process changes for Ryplazim, a c...

Use of Placebo is Necessary Only in Certain Types of Oncology Trials: USFDA In a new draft guidance released, the USFDA is questioning whether or not the use of a placebo in a double-blind, randomized clinical trial is always necessary. The FDA said sometimes the use of a placebo can present practical or ethical co...

AbbVie Receives USFDA Approval for Imbruvica Plus Rituximab as First Chemotherapy-Free Combination Treatment for Waldenström's Macroglobulinemia Adults AbbVie announced that the USFDA approved Imbruvica (ibrutinib) plus rituximab (Rituxan) for the treatment of adult patients with Waldenström's macroglobulinemia (W...

AbbVie’s Orilissa for Endometriosis Pain Management Receives FDA Approval AbbVie in cooperation with Neurocrine Biosciences announced that the U.S. FDA approved Orilissa (elagolix), the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe e...

Positive Phase 1 data supports Cyclacel’s plans for CDK2/9 inhibitor CYC065 Cyclacel faced a big failure in for its late-stage drug for leukemia just a year ago hitting hard on its shares. After that the attention was shifted towards an early-stage CDK inhibitor. As per the latest results presented by the company CD...

Takeda revealed on Wednesday that it is thinking to obtain Shire, which led to rise in its share by 25 percent. It also revealed that there has been no approach made to Shire's board and the proposal is at a "preparatory and exploratory" stage. No information about the investment was revealed by the Japanese drug ma...

Systemic Lupus Erythematosus (SLE) is a chronic, multisystem, inflammatory autoimmune disease which leads to weakening of the immune system. It results in systemic inflammation which affects multiple organs such as kidneys, the tissue lining the lungs (pleura), heart (pericardium), and brain. Acute Cutaneous Lupus, ...

AbbVie aims for best-in-class psoriasis prospect The last few years have seen a wave of new biologics take the psoriasis market by storm. But a best-in-class product may still be on its way. AbbVie prospect risankizumab showed it could bring 47% of patients to complete skin clearance by week 16 of treatment in a pha...

Merck sells biosimilars business to Fresenius Merck has divested its biosimilars business to fellow German drug maker Fresenius in a deal potentially worth 670 million euros. The drug maker said the move is aligned with a strategy of focusing on innovative medicines while enabling it to exploit its biosimilars portf...